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ABSTRACT
Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of 
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment 
option even in the first-line setting. ICIs can block inhibitory pathways that restrain the 
immune response against cancer, restoring and sustaining antitumor immunity. Currently, 
there are 4 PD-1/PD-L1 blocking agents available in clinics, and immunotherapy-based 
regimen alone or in combination with chemotherapy is now preferred option. Combination 
trials assessing combination of ICIs with chemotherapy, targeted therapy and other 
immunotherapy are ongoing. Controversies remain regarding the use of ICIs in targetable 
oncogene-addicted subpopulations, but their initial treatment recommendations remained 
unchanged, with specific tyrosine kinase inhibitors as the choice. For the majority of 
patients without targetable driver oncogenes, deciding between therapeutic options can be 
difficult due to lack of direct cross-comparison studies. There are continuous efforts to find 
predictive biomarkers to find those who respond better to ICIs. PD-L1 protein expressions by 
immunohistochemistry and tumor mutational burden have emerged as most well-validated 
biomarkers in multiple clinical trials. However, there still is a need to improve patient 
selection, and to establish the most effective concurrent or sequential combination therapies 
in different NSCLC clinical settings. In this review, we will introduce currently used ICIs in 
NSCLC and analyze most recent trials, and finally discuss how, when and for whom ICIs can 
be used to provide promising avenues for lung cancer treatment.
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INTRODUCTION
Immune checkpoint proteins, such as PD-1 or CTLA-4 emerged as promising targets of 
immunotherapy, and have improved clinical outcomes of non-small-cell lung cancer (NSCLC) 
patients tremendously. Currently, the anti-PD-1 agent pembrolizumab is approved for use 
as first- and second-line therapy in patients with advanced NSCLC whose tumors express 
PD-L1 in immunohistochemistry analysis (1,2). Nivolumab (anti-PD-1) and atezolizumab 
(anti-PD-L1) are both indicated for use as second-line therapies regardless of PD-L1 
expression (1,3). Durvalumab (anti-PD-L1) is approved as a maintenance therapy in patients 
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with unresectable, stage 3 NSCLC whose disease has not progressed following concurrent 
platinum-based chemoradiotherapy (4). However, many issues are still not resolved regarding 
the biomarker status, choice in the first-line setting, immunotherapy in oncogene-addicted 
tumors, and how to combine immunotherapy with other agents.
NSCLC is a heterogeneous disease that is categorized into 2 broad histologic subtypes, 
adenocarcinoma and squamous cell carcinoma. Recent investigation of tumor immune 
microenvironment suggested that lung adenocarcinoma and squamous cell carcinoma 
show significant differences in immune landscape (5). Understanding the differences in 
immune microenvironment may suggest heterogeneous response to immunotherapy. Several 
microenvironmental factors differentially induce lung adenocarcinoma and squamous cell 
carcinoma immune subtypes, as well as immune checkpoint expression (6). For example, 
tumor-associated macrophages are key immune cells in lung squamous cell carcinoma, 
whereas regulatory B cells play immunosuppressive role in lung adenocarcinoma. In 
addition, the complexity of immune landscape of NSCLC arises from molecular subtype, 
oncogenic drivers, nonsynonymous mutational load, tumor aneuploidy, clonal heterogeneity 
and tumor evolution (7).
Tumor expression of PD-L1 has been most widely investigated as a predictive marker of 
response, but the sensitivity and specificity of this approach is modest (8,9). PD-L1 testing 
shows variable results because of the different Abs and cutoff values used (10), thus PD-L1 
alone cannot accurately reflect the complexity of the tumor microenvironment involved in 
the response to immunotherapy. At the genomic level, tumor mutational burden (TMB) has 
been correlated with the clinical response to anti-PD-1 therapy and associated with favorable 
responses in smokers (11). The role of TMB as a marker predictive of response has been also 
evaluated in several clinical trials (CheckMate026, CheckMate568, CheckMate227) (12-14), 
which showed that patients with high TMB showed enhanced response to immunotherapy, 
regardless of PD-L1 expression. However, overall survival (OS) was not affected by TMB 
alone, and further understanding of the role of TMB as a biomarker is warranted before the 
integration into clinical practice.
Recent pivotal studies have assessed the role of immunotherapy in previously untreated 
metastatic NSCLCs in both squamous and nonsquamous histology, and 4 studies have 
shown an OS benefit from adding PD-1 or PD-L1 inhibitor to standard chemotherapy 
(KEYNOTE-189, IMpower150, IMpower130, KEYNOTE-407). Chemotherapy-sparing 
regimens such as PD-1 or PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor 
have also demonstrated a survival benefit in biomarker-selected, treatment-naïve 
NSCLC patients (KEYNOTE-024, KEYNOTE-042, and CheckMate227). Therefore, it is 
recommended that treatment-naïve, metastatic NSCLC patients receive 1st line treatment 
with immunotherapy, alone or in combination with chemotherapy. The only subsets of 
patients that should not receive first-line immunotherapy regimens are those with genomic-
driven lung cancer, such as EGFR-mutant or ALK-positive NSCLC. First-line treatment with a 
tyrosine kinase inhibitor (TKI) is recommended, and guidelines for genomic testing in newly 
diagnosed metastatic NSCLC remain unchanged.
In this review, we focus on pivotal clinical trials (Table 1) which changed the treatment 
landscape in advanced, stage 4, NSCLC and discuss open issues on how to choose the best 
therapeutic strategy and to select patients for the different treatment options.
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EFFICACY OF KEY TRIALS
PD-1/PD-L1 inhibitor monotherapy in previously treated NSCLC
Three agents (nivolumab, pembrolizumab, atezolizumab) have been investigated for efficacy 
in phase III trials involving previously treated NSCLC patients.
In the open-label, randomized, phase III CheckMate017 trial, nivolumab was compared with 
docetaxel in the second-line setting in NSCLC patients with squamous histology (1). Patients 
were 1:1 randomized to receive either nivolumab 3 mg/kg every 2 weeks or docetaxel 75 mg/
m2 every 3 weeks until disease progression or unacceptable toxicity. Nivolumab showed a 
significant OS benefit (9.2 months vs. 6.0 months; hazard ratio [HR], 0.59; 95% confidence 
interval [CI], 0.44–0.79; p<0.001), and the objective response rate (ORR) was 20% in the 
nivolumab arm, as compared to 9% in the docetaxel arm. The expression of PD-L1 stratified 
at 1%, 5%, or 10% was not found to be predictive of benefit. Treatment-related adverse events 
(AEs) occurred less frequently in nivolumab arm (58% any grade and 7% grade 3 or 4 AEs vs. 
86% any-grade and 55% grade 3 or 4 AEs) compared with docetaxel arm.
CheckMate057 trial, which assessed efficacy of nivolumab compared to docetaxel in the 
second-line setting in NSCLC patients with nonsquamous histology also showed survival 
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Table 1. Pivotal studies of ICIs in advanced NSCLC
Study name Phase Histology, PD-L1 Line of 
treatment




Hazard ratio (95% Confidence 
interval, p value)
First-line ICI only








mOS 30.0 months 0.63 (0.47–0.86), p=0.002








mOS 16.7 months 0.85 (0.71–0.93), p=0.0018








mOS 14.4 months 1.02 (0.80–1.30), p=NS
MYSTIC III NSCLC Treatment-
naïve




mOS 16.3 months (D) D vs. Chemotherapy:  
0.76 (0.56–1.02). p=NS
mOS 11.9 months (D+Tr) D+Tr vs. Chemotherapy:  
0.85 (0.61–1.17), p=NS
First-line ICI+Chemotherapy combination






12-month OS 69.2% 0.49 (0.38–0.64), p<0.001





B/Pac/C±atezolizumab mOS 14.7 
months
mOS 19.2 months 0.78 (0.64–0.96), p=0.02
IMpower132 III Nonsquamous Treatment-
naïve
Pem/P±atezolizumab mPFS 5.2 
months
mPFS 7.6 months 0.60 (0.49–0.73), p<0.0001
KEYNOTE-407 III Squamous Treatment-
naïve
T/C±pembrolizumab mOS 11.3 
months
mOS 15.9 months 0.64 (0.49–0.85), p<0.001
IMpower131 III Squamous Treatment-
naïve
Nab/C±atezolizumab mPFS 5.6 
months
mPFS 6.3 months 0.715 (0.603–0.848), p=0.0001
Later-line ICI
CheckMate017 III Squamous Second or 
later
Nivolumab vs. docetaxel mOS 6.0 
months
mOS 9.2 months 0.62 (0.47–0.80)
CheckMate057 III Nonsquamous Second or 
later
Nivolumab vs. docetaxel mOS 12.2 
months
mOS 9.5 months 0.75 (0.63–0.91)




Pembrolizumab 2 mg/kg or  
10 mg/kg vs. docetaxel
mOS 8.5 
months
2 mg/kg: mOS 10.4 
months
2 mg/kg: 0.71, p=0.0008
10 mg/kg: mOS 12.7 
months
10 mg/kg: 0.61, p<0.0001
OAK III NSCLC Second or 
later
Atezolizumab vs. docetaxel mOS 9.6 
months
mOS 13.8 months 0.73 (0.62–0.87), p=0.0003
ICI, immune checkpoint inhibitor; NSCLC, non-small-cell lung cancer; OS, overall survival; PFS, progression free survival.
benefit for nivolumab (1). The same dose and schedule of nivolumab and docetaxel were used 
as in CheckMate017 trial, and the median OS was superior in the nivolumab arm (12.2 months 
vs. 9.4 months; HR, 0.73; 95% CI, 0.59–0.89; p<0.002). The ORR was 19% for nivolumab and 
12% for docetaxel, and efficacy was greater with nivolumab at pre-specified PD-L1 expressions 
of 1%, 5% or 10%. Treatment-related AEs occurred less frequently in nivolumab arm (69% any-
grade and 10% grade 3 or 4 AEs vs. 88% any-grade and 54% grade 3 or 4 AEs).
The 3-year OS data were recently presented, showing ongoing progression free survival (PFS) 
and OS benefits for nivolumab for both the squamous and nonsquamous histologies (15). 
The 3-year OS rates for CheckMate017 and CheckMate057 were 16% and 18% respectively, 
and among patients who showed response to nivolumab, 26% and 23% showed ongoing 
responses, respectively.
KEYNOTE010 trial was an open-label, phase II/III trial which randomized NSCLC patients 1:1:1 
to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m2 every 
3 weeks (2). Both squamous and nonsquamous histologies were included in this trial, and 
patients were required to have tumors expressing PD-L1. The OS was superior for both doses of 
pembrolizumab compared to docetaxel (10.4 months for pembrolizumab 2 mg/kg, 12.7 months 
for pembrolizumab 10 mg/kg, and 8.5 months for docetaxel). Patients who expressed PD-L1 
expression of ≥50% showed greater benefit with pembrolizumab, and the median PFS was 
also statistically improved in these group of patients. Safety was improved for patients in the 
pembrolizumab arm, grade 3 or greater toxicities occurring at 13% in pembrolizumab 2 mg/kg 
arm, 16% in pembrolizumab 10 mg/kg arm, and 35% in docetaxel arm.
OAK trial evaluated the efficacy and safety of atezolizumab compared with docetaxel in 
NSCLC patients of both squamous and nonsquamous cell histologies (3). PD-L1 expression 
was not required for eligibility and patients were randomized to receive either atezolizumab 
1,200 mg or docetaxel 75 mg/m2 every 3 weeks. The median OS was prolonged in the 
atezolizumab arm compared to docetaxel arm (13.8 months vs. 9.6 months; HR, 0.73; 95% 
CI, 0.62–0.87; p=0.0003), and benefit was consistent regardless of PD-L1 expression. The 
greatest OS benefit was observed in patients having highest PD-L1 expression (20.5 months 
vs. 8.9 months; HR, 0.41; 95% CI, 0.27–0.64; p<0.0001). Intriguingly, patients with brain 
metastases seemed to benefit from atezolizumab treatment in a subgroup analysis, which was 
not observed in other studies with PD-1 inhibitors (1,16). Atezolizumab had a better safety 
profile, showing fewer treatment-related AEs compared to docetaxel (15% vs. 43%).
Overall, the above trials showed consistent improvement in OS and ORR with PD-L1 or PD-L1 
inhibitor monotherapy compared with standard chemotherapy, with less toxicity. However, the 
trials showed heterogeneous cut-offs and diagnostic methods for PD-L1 testing, and whether 
PD-L1 expression should be required in selecting patients for second-line immunotherapy remains 
unclear. Several immunohistochemistry assays are available for evaluating PD-L1 expression 
levels (17). The 22C3 pharmDx assay (Agilent) was used in the pivotal pembrolizumab studies 
and it is approved as a companion diagnostic assay to categorize PD-L1 expression on tumor cells 
according to the tumor proportion score. In addition, 28-8 PharmDx (Agilent) was recognized as 
a complementary diagnostic assay of nivolumab based on evidence that patients with positive PD-
L1 expression in tumor cells have a higher clinical benefit of nivolumab. The Ventana platform was 
used to develop the SP142 Abs in conjunction with atezolizumab, but recent study sponsored by the 
National Comprehensive Cancer Network and the Blueprint Project showed that SP142 had lower 
sensitivity because pathologists do not concordantly read PD-L1 expression on immune cells (18).
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PD-1/PD-L1 inhibitor monotherapy in previously untreated NSCLC
The KEYNOTE-024 and -042 studies compared the efficacy of pembrolizumab monotherapy 
to standard platinum-based chemotherapy in previously untreated NSCLC patients. The 
phase III KEYNOTE-024 trial enrolled the patients with squamous and nonsquamous 
NSCLC with PD-L1 expression on at least 50% of the tumor cells (8). The results showed that 
pembrolizumab had superior PFS compared to chemotherapy (10.3 months vs. 6.0 months; 
HR, 0.50; 95% CI, 0.37–0.68; p<0.001). The frequency of treatment-related AEs of any grade 
and grade ≥3 were significantly lower in the pembrolizumab arm than in the chemotherapy 
arm (73.4% vs. 90% and 26.6% vs. 53.3%, respectively). According to KEYNOTE-024 trial, 
pembrolizumab monotherapy is now regarded as a standard of care therapy for NSCLC 
patients (squamous or nonsquamous histology) with PD-L1 expression of at least 50%.
The KEYNOTE-042 trial assessed the efficacy of pembrolizumab monotherapy in patients 
with PD-L1 expression on at least 1% of tumor cells (19). NSCLC patients with squamous 
or nonsquamous histologies were randomized 1:1 to receive either pembrolizumab 200 mg 
or platinum-based chemotherapy, without crossover to pembrolizumab. Pembrolizumab 
monotherapy significantly improved OS in all pre-specified PD-L1 expression subgroups 
(TPS≥1%, ≥20%, ≥50%). The magnitude of OS benefit was greatest in the patients with 
TPS≥50% (20 months vs. 12.2 months; HR, 0.69; 95% CI, 0.56–0.85; p=0.0003), but the 
OS benefit was not seen patients with TPS ≥1%–49%. These results suggest that patients 
with PD-L1 TPS≥50% were driving the OS benefit, which is consistent with the results from 
KEYNOTE-024 trial.
On the contrary, CheckMate026 trial, a phase III study of nivolumab versus platinum-based 
chemotherapy in patients with treatment-naïve advanced NSCLC with a PD-L1 TPS of ≥1%, 
did not show any clinical benefit (20). In the primary efficacy analysis of patients with a PD-L1 
TPS of ≥5%, nivolumab did not show significant improvement in either PFS or OS. Additional 
exploratory subgroup analyses also did not show any significant difference in PFS or OS in 
patients with a PD-L1 TPS≥50%. Of note, an exploratory analysis was conducted to see the role 
of TMB, and patients with high TMB (as defined as ≥243 missense mutations) showed higher 
response rate (47% vs. 28%) and prolonged PFS (9.7 months vs. 5.8 months; HR, 0.62; 95% 
CI, 0.38–1.00). However, no significant difference was observed in OS regardless of TMB.
MYSTIC trial compared both durvalumab monotherapy and durvalumab in combination 
with tremelimumab with the platinum-doublet chemotherapy in the first-line setting in 
patients 25% or greater PD-L1 expression (21). This trial, however, did not meet its primary 
endpoint of improved PFS compared with the chemotherapy in either the durvalumab 
monotherapy or durvalumab plus tremelimumab. Therefore, pembrolizumab remains the 
only FDA-approved single-agent, immune checkpoint inhibitor (ICI) in the first-line setting 
in advanced NSCLC patients.
PD-1/PD-L1 inhibitor in combination with chemotherapy
The addition of PD-1/PD-L1 inhibitor to standard chemotherapy in treatment-naïve NSCLC 
patients was investigated, regardless of PD-L1 expression. The rationales behind combining 
immunotherapy to chemotherapy are that cytotoxic chemotherapeutic agents may 1) induce 
immunological activity (22); 2) cytotoxic agents may increase presentation of tumor Ags (23); 
3) reduce regulatory T cells (24) and myeloid derived suppressor cells (25); 4) induce PD-L1 
expression on tumor cells (23).
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KEYNOTE-189 was a phase III, placebo-controlled double-blinded trial which assessed 
first-line platinum-based chemotherapy with or without pembrolizumab in EGFR/ALK-wild 
type, nonsquamous NSCLC patients (26). The ORR was 47.6% in the pembrolizumab-
chemotherapy arm vs. 18.9% in the placebo-chemotherapy arm (p<0.001). The median OS 
was not reached at the time of analysis for the pembrolizumab-chemotherapy arm vs. 11.3 
months for placebo-chemotherapy arm (HR, 0.49; 95% CI, 0.38–0.64; p<0.001), and the 
OS advantage was achieved in all PD-L1 subgroups. The median PFS was 8.8 months vs. 4.9 
months (HR, 0.52; 95% CI, 0.43–0.64; p<0.001), but no PFS benefit was evident adding 
pembrolizumab in patients with PD-L1 TPS<1%. In terms of safety, neither an increase in AEs 
nor an increase in immune-mediated AEs were reported in pembrolizumab-chemotherapy 
arm. On the basis of KEYNOTE-189 results, pembrolizumab in combination with pemetrexed 
and carboplatin as first-line treatment in metastatic nonsquamous NSCLC became a new 
standard, regardless of PD-L1 expression (27).
Impower150 evaluated the role of atezolizumab combined with chemotherapy for the first-
line treatment of metastatic nonsquamous NSCLC. Patients were randomized to 3 groups: 
atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP); ACP; and BCP. While the 
data comparing ABCP and BCP are available, both the median PFS and OS were improved 
in the atezolizumab-containing arm (PFS, 8.3 months vs. 6.8 months; OS, 19.2 months vs. 
14.7 months) compared with the patients treated with BCP (28). Of note, patients with EGFR 
and ALK alterations were included in this trial, and they also had benefit from atezolizumab-
containing arm (HR, 0.59; 95% CI, 0.37–0.94). A higher incidence of grade ≥3 AEs was 
observed in the atezolizumab-containing arm (55.7% vs. 47.7%), mainly anorexia, nausea, 
diarrhea, neutropenia, thrombocytopenia and febrile neutropenia. A total of 77.% of the 
immune-related AEs in ABCP group were grade 1 or 2 and manageable, and none were grade 5.
IMpower132 also assessed the role of atezolizumab in first-line chemotherapy combinations 
for advanced nonsquamous NSCLC. There was an improvement in PFS in the atezolizumab-
containing arm (7.6 months vs. 5.2 months) and benefit was seen in both PD-L1 positive and 
negative group (29).
KEYNOTE-407 and IMpower131 trial investigated the efficacy of PD-1/PD-L1 inhibitor in 
metastatic squamous NSCLC in combination with chemotherapy. In KEYNOTE-407 trial, 
patients were randomized to receive 4 cycles of carboplatin and a taxane with or without 
pembrolizumab (30). As expected, patients in the pembrolizumab-containing group showed 
a significantly improved OS compared with those in the chemotherapy group (15.9 months 
vs. 11.3 months; HR, 0.64; 95% CI, 0.49–0.85; p<0.001). Benefit was seen in all PD-L1 TPS 
groups, and pembrolizumab did not significantly increase treatment-related toxicity.
IMpower131 trial examined atezolizumab with chemotherapy consisting of carboplatin with 
either paclitaxel (ACP) or nab-paclitaxel (ACnP) against carboplatin plus nab-paclitaxel 
(CnP) control (31). While the results were positive in terms of its primary endpoint of median 
PFS for ACnP versus CnP (6.3 months vs. 5.6 months; HR, 0.715; 95% CI, 0.603–0.848; 
p=0.0001), the median OS were not different between 2 groups.
Immunotherapy combinations
In CheckMate227, treatment-naïve patients with advanced NSCLC were randomized to 
nivolumab plus ipilimumab, nivolumab, and histology-based chemotherapy arms (14). 
According to PD-L1 expression, patients were divided into PD-L1≥1% and <1%, and further 
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randomized 1:1:1 to nivolumab plus ipilimumab, platinum-based chemotherapy, or nivolumab 
monotherapy (PD-L1≥1% group) or nivolumab plus platinum-based chemotherapy (PD-
L1<1% group). The study protocol was later modified to include a co-primary endpoint of 
PFS in patients with high TMB, as defined by ≥10 mutations per megabase. This was due to 
the previous finding that high TMB was associated with enhanced response rate and PFS, 
independent of tumor PD-L1 expression (11). Among patients with high TMB, nivolumab plus 
ipilimumab arm showed a significantly prolonged PFS than chemotherapy arm (7.2 months 
vs. 5.5 months; HR, 0.58; 95% CI, 0.41–0.81; p<0.001). However, in patients with lower TMB, 
median PFS was shorter in patients in nivolumab plus ipilimumab arm compared with those 
in chemotherapy arm (3.2 months vs. 5.5 months; HR, 1.07, 95% CI, 0.56–1.10). However, the 
median OS was not significantly different among high TMB (32). Incidence of grade 3 or higher 
AEs were similar (31.2% in nivolumab plus ipilimumab vs. 36.1% in chemotherapy arm).
In CheckMate568, the association of efficacy with PD-L1 expression and TMB was assessed in 
patients who received first-line nivolumab plus ipilimumab (33). Higher response rates and 
improved PFS were observed in patients with TMB of 10 or more mut/Mb versus TMB of fewer 
than 10 mut/Mb, irrespective of PD-L1 expression. This analysis supported TMB of 10 or more 
mut/Mb as a clinically meaningful cutoff for response and PFS in patients receiving first-line 
nivolumab plus ipilimumab.
Currently, novel targets and combinations are underway to enhance antitumor immune 
response. Supplementary Table 1 shows a selected list of novel immunotherapy trials 
in clinical development in solid tumors and lymphomas. Novel combination strategies 
can be classified according to mechanism of action: 1) Co-inhibitory blockade; 2) 
Costimulation; 3) Bispecific T cell engager Ab constructs; and 4) Priming. First of all, 
agents that block co-inhibitory receptors apart from CTLA-4 and PD-1/PD-L1 include 
V-domain immunoglobulin suppressor of T cell activation, lymphocyte-activation gene-3 
(LAG-3), T cell immunoglobulin- and mucin-domain-containing module 3 (TIM-3), T cell 
immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory 
motif domain, and B7-H3. Since a considerable proportion of patients remain unresponsive 
to immunotherapeutics targeting the inhibitory receptors CTLA-4, PD-1 or PD-L1, targeting 
novel inhibitory pathways in combination with current immunotherapies may improve 
clinical outcomes. Therefore, clinical trials involving novel checkpoint targets such as 
V-domain immunoglobulin suppressor of T cell activation /PD-1H (NCT02671955), B7-H3 
(NCT01391143, NCT02475213, NCT00844064), LAG-3 (NCT01968109, NCT02460224, 
NCT00732082, NCT00349934) are ongoing, often in combination with PD-1 inhibitors. A 
first-in-human study of human LAG-3 monoclonal Ab (REGN3767) in combination with 
PD-1 inhibitor (cemiplimab) was recently reported, and early efficacy signals were detected 
with acceptable safety profiles (34). Secondly, costimulatory agents are OX40, GITR, ICOS, 
4-1BB, and CD40. Besides, costimulatory molecules such as OX40, GITR, ICOS, 4-1BB 
(CD137), CD40 can augment immunological responses against malignant cells. Bispecific 
Abs, vaccines, oncolytic viruses and cytokines are also passive and active immunotherapies. 
Bispecific T cell engager Ab constructs are a type of fusion protein that is designed by linking 
the targeting regions of 2 Abs. One arm of the molecule binds to the surface of cytotoxic 
T cells, and the other arm binds to a specific protein found primarily on tumor cells (35). 
Moreover, bispecific Abs to TIM-3 have also been developed. RO7121661 (bispecific Ab to 
TIM-3 and PD-1) and LY3415244 (bispecific Ab to TIM-3 and PD-L1) are currently under 
clinical investigation. Oncolytic viruses selectively kill cancer cells and stimulate the immune 
system (e.g., T-Vec), while dendritic cell vaccines (e.g., sipuleucel-T) involve the extraction of 
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dendritic cells from the patient, exposure to cancer cells or Ags, and reintroduction of now 
active immune cells to the patient (36). STimulator of INterferon Genes agonist, a phase 
1b study of MIW815 in combination with PD-1 inhibitor (PDR001), was recently reported in 
patients with advanced solid tumors. The preliminary response was higher in patients with 
moderate to high baseline PD-L1 expression (ORR 25.0%) as compared to patients with low 
PD-L1 expression (ORR 4.5%), and increase in CD8+ T cells in tumor after drug injection 
was suggested as a pharmacodynamics marker, reflecting therapeutic benefit (37). Further 
understanding of the basic biology of these novel targets is imperative to the development of 
effective cancer immunotherapy.
PD-1/PD-L1 inhibitor in EGFR and ALK altered patients
The role of PD-1/PD-L1 inhibitor in oncogene-addicted NSCLC is still unclear, and currently 
TKIs are the standard treatment options in patients with EGFR- or ALK-altered tumors. 
Targeted therapy in combination with PD-1/PD-L1 inhibitors have been tried, trials have been 
prematurely stopped due to toxicity issues. A phase 1b TATTON trial testing osimertinib 
(EGFR TKI) plus nivolumab was closed early due to high incidence of interstitial lung disease 
(38%) (38). In addition, the CAURAL phase III trial evaluating the combination of osimertinib 
and durvalumab in EGFR T790M positive patients was also prematurely stopped due to 
safety concerns. However, in ALK-rearranged NSCLC patients, combination of alectinib (ALK 
TKI) and atezolizumab showed acceptable toxicity, but ORR was not improved compared to 
alectinib alone (39). Due to high incidence of high-grade toxicities with combination of TKI 
and immunotherapy, further development should be cautiously considered.
A single agent pembrolizumab was investigated in a phase II trial of patients with EGFR-
mutant, PD-L1-positive (≥1%) advanced NSCLC. All patients were treatment-naïve, but after 
enrolling 11 out of 25 patients, the trial was terminated early due to lack of efficacy (40). To 
date, ICIs are not considered effective in oncogene-addicted patients. Other interventional 
strategies are underway to evaluate the combination of ICIs plus chemotherapy in the 
resistant setting (NCT02864251, NCT03256136, NCT03515837), as well as combination with 
anti-CD73 therapies (NCT03454451) based on preclinical rationale (41).
PATIENT SELECTION AND BIOMARKERS
Figure 1 shows the first-line treatment algorithm. So far, PD-L1 expression by 
immunohistochemistry is the only approved biomarker to select patients for immunotherapy. As 
mentioned earlier, there are different methods of cutoffs and interpretation because companies 
use different PD-L1 assays (Dako 28-8, Dako 22C3, Ventana SP142, Ventana SP263 for nivolumab, 
pembrolizumab, atezolizumab and durvalumab, respectively). Moreover, even PD-L1 negative 
patients may respond to anti-PD-1/PD-L1 inhibitor, while some PD-L1 highly positive patients do 
not show response. Therefore, PD-L1 expression is still an incomplete marker.
According to results of CheckMate227 trial, TMB was considered as a potential and new 
biomarker, independently from PD-L1 expression. Recently, blood TMB was also evaluated 
in pretreated NSCLC patients who were enrolled in OAK and POPLAR studies (42), in 
treatment-naïve NSCLC patients in a phase II, B-F1RST trial receiving atezolizumab (43), 
and in patients in MYSTIC trial (21). These studies suggested that TMB was feasible in the 
majority of patients, and the rate of high TMB (≥10 mut/megabase) was between 23% and 
30%. In addition, blood TMB and tissue TMB correlated significantly in the pooled analysis, 
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suggesting that TMB may be more easily tested on blood rather than on tumor tissues. 
However, like PD-L1, TMB results may vary according to different platforms of sequencing, 
and testing costs are high for routine clinical practice. Although TMB can be complementary 
to PD-L1 immunohistochemistry, future prospective randomized studies are required to 
assess the clinical value of TMB as a predictive biomarker for anti-PD-1/PD-L1 inhibitors.
TOXICITY PROFILES
Immune-related adverse events (irAEs) are ICI-mediated inflammatory side effects (44). 
The pathophysiology underlying irAEs is largely unknown but is believed to be related to the 
disruption of immunologic homeostasis (45). Recent studies suggest that the occurrence of 
irAEs predicts the treatment efficacy of ICIs in NSCLC (46,47), but at the same time, is more 
likely to be associated with treatment discontinuation. Adverse events from ICIs can affect 
one or several different systemic organ systems. Toxicities can occur as various symptoms 
and signs: skin (rash, pruritus), gastrointestinal (colitis), liver (transaminitis), pancreas 
(pancreatitis), endocrine (thyroiditis, adrenal insufficiency, hypophysitis, type 1 diabetes 
mellitus), lung (pneumonitis), kidney (proteinuria), eye (uveitis, episcleritis), nervous system 
(myasthenia gravis, peripheral neuropathy, encephalitis, transverse myelitis), cardiovascular 
(myocarditis), and musculoskeletal (arthritis). The incidence of grade 3 or higher toxicities 
is 7% to 13% in NSCLC patients treated with PD-1 axis inhibitors (48). As ICIs increase 
the activity of the immune system, T cells can attack healthy cells in the body, causing 
inflammatory conditions that mimic a range of autoimmune conditions, some of which can 
be serious (49). These immune-related AEs can occur at any time during treatment or even 
after treatment is discontinued. The severity of AEs can range from asymptomatic to severe 
or life-threatening and they may cumulate over the course of therapy. Combination treatment 
may increase the severity of adverse events, so more caution is required. Regular monitoring 
including laboratory tests and physical exams needs to be conducted to detect any potential 
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Pembrolizumab + platinum-pemetrexed (KN-189)
Atezolizumab + platinum-pemetrexed (IMP-132)
Atezolizumab + carboplatin-Nab-paclitaxel (IMP-130)
Atezolizumab + bevacizumab+carboplatin-paclitaxel (IMP-150)
Pembrolizumab + carboplatin-paclitaxel (KN-407)
Atezolizumab + carboplatin-Nab-paclitaxel (IMP-131)
Figure 1. First-line treatment algorithm. Dashed boxes indicate treatments which did not receive approval from regulatory agencies yet. 
TMB, tumor mutational burden.
immune-related AEs, because most AEs can be managed effectively if detected and treated 
early (50).
TREATMENT DURATION
While current dosing and duration guidelines are based primarily on initial clinical trials 
conducted for approval of the ICIs, the optimal duration of treatment still needs to be 
explored. Similar to chemotherapeutic agents, the duration of treatment of all 5 currently 
approved PD-1/PD-L1 inhibitors are until disease progression or unacceptable toxicity. 
However, since immunotherapy work with a completely different mechanism compared to 
chemotherapy, using the same therapy duration may not be optimal. For example, it remains 
undecided whether we can discontinue the therapy in patients with complete response. In 
a retrospective study, they suggest stopping treatment is a viable option in patients with 
complete response as the durability of response is maintained in about 80%–90% of patients 
(51). Treatment holidays and possibly stopping immune based therapy early is a concept that 
needs further research using novel trial designs.
HYPERPROGRESSION
There is an emerging evidence that PD-1/PD-L1 inhibitors can lead to hyperprogressive 
disease (HPD), similar to a flare-up of tumor growth leading to dismal outcome. A recent 
meta-analysis to identify baseline patient factors associated with risks of developing HPD was 
reported. Although there was no standard definition of HPD, the incidence of HPD ranged 
from 1% to 30% (52). In this report, they identified serum LDH above the upper normal 
limit, more than 2 metastatic sites, liver metastases, Royal Marsden Hospital prognostic 
score of 2 or above as positively associated with HPD, and positive PD-L1 expression status 
that was inversely correlated with HPD. In another analysis, genomic alterations in genes 
such as EGFR, MDM2/4 and DNMT3A were associated with HPD (53). In a recent exploratory 
biomarker analysis of patients with HPD, a lack of pre-existing antitumor immunity 
correlated with HPD, represented by a lower frequency of effector/memory subsets and a 
higher frequency of exhausted T cells populations in patients with HPD (54). Molecular 
mechanisms of hyperprogression are yet to be elucidated.
CONCLUSIONS
Although ICIs have been adopted for a limited amount of time so far, they ushered in a 
new era in the management of advanced NSCLC. Clinicians are now faced with numerous 
options of treatment such as PD-1 inhibitor monotherapy or PD-1/PD-L1 inhibitor plus 
chemotherapy, and a growing number of patients are achieving durable responses. Better 
predictive biomarkers are required to optimize the benefit of immunotherapy, and further 
studies are needed to determine the mechanism of resistance to ICIs and how to overcome 
it. In summary, ICIs have changed the treatment landscape in advanced NSCLC and ongoing 
translational and clinical studies are highly awaited to further improve outcomes for these 
patients. Expanding clinical benefit to the majority of patients and preventing drug resistance 
requires a better understanding of the mechanisms that lead to an effective anti-tumor 
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response. The development of new combination strategies will shed the light to the next 
advances of cancer immunotherapy.
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